EGFR positive
|
Solid Tumor
|
EGFR positive
|
Solid Tumor
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
EGFR positive
|
Lung Cancer
|
EGFR positive
|
Lung Cancer
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
EGFR positive
|
Breast Cancer
|
EGFR positive
|
Breast Cancer
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
cetuximab Sensitive: C2 – Inclusion Criteria
|
EGFR positive
|
NSCLC
|
EGFR positive
|
NSCLC
|
gefitinib + anlotinib Sensitive: C3 – Early Trials
|
gefitinib + anlotinib Sensitive: C3 – Early Trials
|
EGFR positive
|
HCC
|
EGFR positive
|
HCC
|
cetuximab Sensitive: D – Preclinical
|
cetuximab Sensitive: D – Preclinical
|